Thierry Nordmann

Dr. Dr. Thierry Nordmann, MD-PhD, is a Research Group Leader at the Max Planck Institute of Biochemistry (Martinsried, Germany) and Senior Physician at Ludwig Maximilian University (LMU) Hospital's Department of Dermatology and Allergology in Munich. His work focuses on unraveling the molecular architecture of skin diseases through advanced proteomics and AI-driven analysis of clinical samples.

• Education
  • MD (2012), University Hospital Basel/Zürich
  • Dr. med. (2015), University Hospital Basel
  • Dr. phil. nat. (MD/PhD, 2016), University Hospital Basel
  • Board Certification in Dermatology and Venereology (2021)

The Molecular and Spatial Biology of Skin research group explores fundamental mechanisms of inflammation, autoimmunity, and cancer using skin as a model system. Their work integrates mass spectrometry proteomics, spatial omics, and computational frameworks to identify disease-defining molecular signatures with clinical translational potential.

Thierry Nordmann's team has pioneered breakthroughs like the Jak-Inhibitor treatment for toxic epidermal necrolysis (pending patent, 2023). Current research emphasizes precision medicine applications in dermatology.

• Scientific Awards
  • Oscar Gans Prize (2025)

Nordmann's grants include multiple Swiss National Foundation awards (MD-PhD Grant 2013-2015; Early Postdoc Mobility Grant 2021-2022; Postdoc Mobility Grant 2022-2024) and a LEO Foundation Research Grant (2026-2027). He serves as Deputy Head of Biobanking for the International Registry for Toxic Epidermal Necrolysis (IRTEN) and contributes to clinical training as lecturer at University of Zurich.